SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Reneo Pharmaceuticals, Inc. (RPHM) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 44/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — RPHM
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-4.40
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-1.60 |
$0.00 |
$-12.44M |
- |
| 2020 |
$-0.80 |
$0.00 |
$-19.47M |
- |
| 2021 |
$-2.19 |
$0.00 |
$-39.77M |
- |
| 2022 |
$-2.04 |
$0.00 |
$-50.06M |
- |
| 2023 |
$-2.30 |
$0.00 |
$-77.39M |
- |
| 2024 |
$0.00 |
$0.00 |
$0.00 |
- |
| 2025 |
$-4.40 |
$0.00 |
$0.00 |
- |
